Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
Stock Information for Tempest Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.